<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlsource><Section SecID="560" OrdBy="10" Name="General"><Field FieldID="11" OrdBy="20" ID="561" Name="Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Aspirin use and discussion: percentage of women 56 to 79 years of age and men 46 to 79 years of age who discussed the risks and benefits of using aspirin with a doctor or other health provider.&lt;/div&gt;" /></Field><Field FieldID="1" OrdBy="30" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Committee for Quality Assurance (NCQA). HEDIS 2014: Healthcare Effectiveness Data and Information Set. Vol. 1, narrative. Washington (DC): National Committee for Quality Assurance (NCQA); 2013. various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Committee for Quality Assurance (NCQA). HEDIS 2014: Healthcare Effectiveness Data and Information Set. Vol. 2, technical specifications for health plans. Washington (DC): National Committee for Quality Assurance (NCQA); 2013. various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Committee for Quality Assurance (NCQA). HEDIS 2014: Healthcare Effectiveness Data and Information Set. Vol. 3, specifications for survey measures. Washington (DC): National Committee for Quality Assurance (NCQA); 2013. various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Cardiovascular disease, unspecified  (429.2); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Tobacco use disorder  (305.1)"/><FieldValue Value="MSH: Anti-Inflammatory Agents, Non-Steroidal ; Aspirin ; Cardiovascular Diseases ; Chemoprevention ; Coronary Disease ; Hypercholesterolemia ; Hypertension ; Patient Education as Topic ; Risk Factors ; Smoking ; Tobacco Use Disorder "/><FieldValue Value="MTH: Anti-Inflammatory Agents, Non-Steroidal ; Aspirin ; Cardiovascular Diseases ; Chemoprevention ; Coronary heart disease ; Hypercholesterolemia ; Hypertensive disease ; Patient education (procedure) ; risk factors ; Smoking ; Tobacco Use Disorder "/><FieldValue Value="PDQ: acetylsalicyclic acid ; tobacco use disorder "/><FieldValue Value="SNOMEDCT_US: Aspirin ; Aspirin prophylaxis ; At risk of coronary heart disease ; Disorder of cardiovascular system ; Hypercholesterolemia ; Hypertensive disorder ; Non-steroidal anti-inflammatory agent ; Patient education ; Prophylactic chemotherapy ; Risk factor ; Tobacco user "/></Field></Section><Section SecID="563" OrdBy="40" Name="Measure Domain"><Field FieldID="3025" OrdBy="50" ID="564" Name="Primary Measure Domain" Type="picklist-one"><FieldValue Value="Clinical Quality Measures: Process" /></Field><Field FieldID="3026" OrdBy="60" ID="565" Name="Secondary Measure Domain" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field></Section><Section SecID="566" OrdBy="70" Name="Brief Abstract"><Field FieldID="34" OrdBy="80" ID="567" Name="Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure is one component of a two-part survey measure that assesses different facets of managing aspirin use for the primary prevention of cardiovascular disease. This measure uses survey data to assess the percentage of women 56 to 79 years of age&amp;nbsp;and men 46&amp;nbsp;to 79 years who discussed the risks and benefits of using aspirin with a doctor or other health provider. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This measure is collected as part of the CAHPS Health Plan Survey 5.0H, Adult Version (commercial, Medicaid).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See the related National Quality Measures Clearinghouse (NQMC) summary of the National Committee for Quality Assurance (NCQA) measure &lt;a href=&quot;/content.aspx?id=47220&quot; title=&quot;Measure Summary&quot; target=&quot;_blank&quot;&gt;Aspirin use and discussion: percentage of members who are currently taking aspirin, including women 56 to 79 years of age with at least two risk factors for cardiovascular disease (CVD); men 46 to 65 years of age with at least one risk factor for CVD; and men 66 to 79 years of age, regardless of risk factors&lt;/a&gt;. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="21" OrdBy="90" ID="568" Name="Rationale" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The United States Preventive Services Task Force (USPSTF) strongly recommends that clinicians discuss aspirin chemoprevention with adults who are at increased risk (five-year risk greater than or equal to 3 percent) for coronary heart disease (CHD). Discussions with patients should address both the potential benefits and harms of aspirin therapy. The American Diabetes Association (ADA) encourages the use of aspirin therapy (75-162 mg/day) as a primary prevention strategy in patients with type 1 or type 2 diabetes who are at increased cardiovascular risk, including those who are 40 years of age and older or who have additional risk factors (e.g., family history of cardiovascular disease [CVD], hypertension, smoking, dyslipidemia, albuminuria).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In 2004, CHD was an underlying or contributing cause of death for 451,300 people and accounted for 1 of every 5 deaths in the United States (U.S.). The prevalence of CHD for both sexes in 2005 was nearly 16 million people, or 7.3 percent of the American population. The cost of cardiovascular diseases and stroke in the U.S. for 2008 was estimated at $448.5 billion, including health expenditures and lost productivity resulting from morbidity and mortality (indirect costs). Evidence shows that age is a strong demographic factor for CHD. It is projected that by 2030, 1 in 5 Americans will be 65 or older. The need for CHD management is essential.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Aspirin treatment has been shown to prevent one cardiovascular event over an average follow-up of 6.4 years. This means that, on average in a 6.4 year time period, the use of aspirin therapy results in a benefit of three cardiovascular events prevented per 1,000 women and four events prevented per 1,000 men. Aspirin has been shown to reduce CHD in patients with peripheral arterial disease, as well.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Aspirin therapy (75-162 mg/day) is also recommended as a secondary prevention strategy in patients who have diabetes and a history of CVD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Specifications are consistent with current recommendations from USPSTF and ADA.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3500" OrdBy="100" ID="569" Name="Evidence for Rationale" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Physicians Task Force on Adult Immunization and Infectious Diseases Society. Guides for adult immunization. 3rd ed. Philadelphia (PA): American College of Physicians; 1994. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Heart Association. Heart disease and stroke statistics - 2008 update. Dallas (TX): American Heart Association; 2008. 43 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006 Jan 18;295(3):306-13. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16418466&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Berra K, Miller NH, Fair JM. Cardiovascular disease prevention and disease management: a critical role for nursing. J Cardiopulm Rehabil. 2006 Jul-Aug;26(4):197-206. [39 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16926682&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kikano GE, Brown MT. Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. Mayo Clin Proc. 2007 May;82(5):583-93. [67 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17511957&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Committee for Quality Assurance (NCQA). HEDIS 2014: Healthcare Effectiveness Data and Information Set. Vol. 1, narrative. Washington (DC): National Committee for Quality Assurance (NCQA); 2013. various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore (MD): Williams &amp; Wilkins; 1996. Chapter 55, Counseling to promote physical activity.  p. 611-624. [128 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="3022" OrdBy="110" ID="570" Name="Primary Health Components" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Aspirin use; cardiovascular disease (CVD)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="23" OrdBy="120" ID="571" Name="Denominator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The number of eligible members who are women 56 to 79 years of age and men 46 to 79 years of age and who responded to the survey (see the related &quot;Denominator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="24" OrdBy="130" ID="572" Name="Numerator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The number of members in the denominator who indicated that their doctor or other provider discussed the risks and benefits of aspirin use to prevent heart attack or stroke (see the related &quot;Numerator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="573" OrdBy="140" Name="Evidence Supporting the Measure"><Field FieldID="3027" OrdBy="150" ID="574" Name="Type of Evidence Supporting the Criterion of Quality for the Measure" Type="picklist-choice"><FieldValue Value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence" /><FieldValue Value="A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences" /><FieldValue Value="A systematic review of the clinical research literature (e.g., Cochrane Review)" /><FieldValue Value="One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal" /></Field><Field FieldID="3501" OrdBy="160" ID="575" Name="Additional Information Supporting Need for the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3072" OrdBy="180" ID="577" Name="Extent of Measure Testing" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="580" OrdBy="210" Name="State of Use of the Measure"><Field FieldID="3029" OrdBy="220" ID="581" Name="State of Use" Type="picklist-one"><FieldValue Value="Current routine use" /></Field><Field FieldID="3030" OrdBy="230" ID="582" Name="Current Use" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field></Section><Section SecID="583" OrdBy="240" Name="Application of the Measure in its Current Use"><Field FieldID="3031" OrdBy="250" ID="584" Name="Measurement Setting" Type="picklist-choice"><FieldValue Value="Managed Care Plans" /></Field><Field FieldID="3032" OrdBy="260" ID="585" Name="Professionals Involved in Delivery of Health Services" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3033" OrdBy="270" ID="586" Name="Least Aggregated Level of Services Delivery Addressed" Type="picklist-one"><FieldValue Value="Single Health Care Delivery or Public Health Organizations" /></Field><Field FieldID="3505" OrdBy="280" ID="587" Name="Statement of Acceptable Minimum Sample Size" Type="picklist-one"><FieldValue Value="Specified" /></Field><Field FieldID="41" OrdBy="290" ID="588" Name="Target Population Age" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Men 46 to 79 years of age; women 56 to 79 years of age&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="42" OrdBy="300" ID="589" Name="Target Population Gender" Type="picklist-one"><FieldValue Value="Either male or female" /></Field></Section><Section SecID="660" OrdBy="310" Name="National Strategy for Quality Improvement in Health Care"><Field FieldID="3522" OrdBy="320" ID="661" Name="National Quality Strategy Aim" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Better Care&lt;/li&gt;&lt;/ul&gt;" /></Field><Field FieldID="3525" OrdBy="330" ID="662" Name="National Quality Strategy Priority" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Health and Well-being of Communities&lt;/li&gt;&lt;li&gt;Person- and Family-centered Care&lt;/li&gt;&lt;li&gt;Prevention and Treatment of Leading Causes of Mortality&lt;/li&gt;&lt;/ul&gt;" /></Field></Section><Section SecID="590" OrdBy="340" Name="Institute of Medicine (IOM) National Health Care Quality Report Categories"><Field FieldID="3163" OrdBy="350" ID="591" Name="IOM Care Need" Type="picklist-choice"><FieldValue Value="Staying Healthy" /></Field><Field FieldID="3164" OrdBy="360" ID="592" Name="IOM Domain" Type="picklist-choice"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="593" OrdBy="370" Name="Data Collection for the Measure"><Field FieldID="3506" OrdBy="380" ID="594" Name="Case Finding Period" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The measurement year&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3054" OrdBy="390" ID="595" Name="Denominator Sampling Frame" Type="picklist-one"><FieldValue Value="Enrollees or beneficiaries" /></Field><Field FieldID="3057" OrdBy="400" ID="598" Name="Denominator (Index) Event or Characteristic" Type="picklist-choice"><FieldValue Value="Patient/Individual (Consumer) Characteristic" /></Field><Field FieldID="3058" OrdBy="410" ID="599" Name="Denominator Time Window" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="55" OrdBy="420" ID="596" Name="Denominator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;The number of eligible members who are women 56 to 79 and men 46 to 79 years of age and who responded to the survey&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul class=&quot;Note&quot; style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Eligible Population&lt;/em&gt;: Men ages 46 to 79 and women ages 56 to 79 as of December 31 of the measurement year who were continuously enrolled during the measurement year (commercial) or for the last six months of the measurement year (Medicaid), and currently enrolled at the time the survey is completed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Allowable Gap&lt;/em&gt;: No more than one gap in enrollment of up to 45 days during the measurement year (commercial). To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Refer to original measure documentation for additional information regarding eligibility and survey questions. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Any response to the following question indicates a cardiovascular disease (CVD) exclusion:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&quot;Has a doctor ever told you that you have any of the following conditions? Check all that apply.&quot; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Exclude any member who selected &lt;em&gt;any&lt;/em&gt; response choice: &quot;A heart attack&quot; or &quot;Angina or coronary heart disease&quot; or &quot;A stroke&quot; or &quot;Any kind of diabetes or high blood sugar.&quot;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3507" OrdBy="430" ID="597" Name="Exclusions/Exceptions" Type="picklist-choice-4"><FieldValue Value="not defined yet" /></Field><Field FieldID="59" OrdBy="440" ID="600" Name="Numerator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;The number of members in the denominator who indicated that their doctor or other provider discussed the risks and benefits of aspirin use to prevent heart attack or stroke&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Refer to the original measure documentation for information regarding survey questions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3061" OrdBy="450" ID="601" Name="Numerator Search Strategy" Type="picklist-one"><FieldValue Value="Fixed time period or point in time" /></Field><Field FieldID="3062" OrdBy="460" ID="602" Name="Data Source" Type="picklist-many"><FieldValue Value="Administrative clinical data" /><FieldValue Value="Patient/Individual survey" /></Field><Field FieldID="3065" OrdBy="470" ID="603" Name="Type of Health State" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3066" OrdBy="480" ID="604" Name="Instruments Used and/or Associated with the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;CAHPS&amp;reg; 5.0H Adult Survey&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="605" OrdBy="490" Name="Computation of the Measure"><Field FieldID="3508" OrdBy="500" ID="606" Name="Measure Specifies Disaggregation" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3067" OrdBy="520" ID="608" Name="Scoring" Type="picklist-many"><FieldValue Value="Rate/Proportion" /></Field><Field FieldID="3068" OrdBy="530" ID="609" Name="Interpretation of Score" Type="picklist-one"><FieldValue Value="Desired value is a higher score" /></Field><Field FieldID="3090" OrdBy="540" ID="610" Name="Allowance for Patient or Population Factors" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3069" OrdBy="550" ID="611" Name="Description of Allowance for Patient or Population Factors" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure requires that separate rates be reported for commercial and Medicaid product lines.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3070" OrdBy="560" ID="612" Name="Standard of Comparison" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field></Section><Section SecID="615" OrdBy="590" Name="Identifying Information"><Field FieldID="73" OrdBy="600" ID="616" Name="Original Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Aspirin use and discussion (ASP).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="74" OrdBy="610" ID="617" Name="Measure Collection Name" Type="text"><FieldValue Value="HEDIS 2014: Health Plan Collection" /></Field><Field FieldID="75" OrdBy="620" ID="618" Name="Measure Set Name" Type="text"><FieldValue Value="Effectiveness of Care" /></Field><Field FieldID="77" OrdBy="630" ID="619" Name="Measure Subset Name" Type="text"><FieldValue Value="Measures Collected through the CAHPS Health Plan Survey" /></Field><Field FieldID="16" OrdBy="650" ID="621" Name="Submitter" Type="orglist"><FieldValue Value="National Committee for Quality Assurance - Health Care Accreditation Organization" /></Field><Field FieldID="17" OrdBy="660" ID="622" Name="Developer" Type="orglist-p"><FieldValue Value="National Committee for Quality Assurance - Health Care Accreditation Organization" /></Field><Field FieldID="79" OrdBy="670" ID="623" Name="Funding Source(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="80" OrdBy="680" ID="624" Name="Composition of the Group that Developed the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;National Committee for Quality Assurance's (NCQA's) Measurement Advisory Panels (MAPs) are composed of clinical and research experts with an understanding of quality performance measurement in the particular clinical content areas.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="81" OrdBy="690" ID="625" Name="Financial Disclosures/Other Potential Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;In order to fulfill National Committee for Quality Assurance's (NCQA's) mission and vision of improving health care quality through measurement, transparency and accountability, all participants in NCQA's expert panels are required to disclose potential conflicts of interest prior to their participation. The goal of this Conflict Policy is to ensure that decisions which impact development of NCQA's products and services are made as objectively as possible, without improper bias or influence.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="19" OrdBy="730" ID="629" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;For commercial and Medicaid members, this measure is collected using the HEDIS (Healthcare Effectiveness Data and Information Set) version of the CAHPS&amp;reg; survey (CAHPS&amp;reg; 5.0H Adult Survey).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;CAHPS&amp;reg; 5.0 is sponsored by the Agency for Healthcare Research and Quality (AHRQ).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3086" OrdBy="740" ID="630" Name="Date of Most Current Version in NQMC" Type="date"><FieldValue Value="2013 Sep" /></Field><Field FieldID="3511" OrdBy="750" ID="631" Name="Measure Maintenance" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3512" OrdBy="760" ID="632" Name="Date of Next Anticipated Revision" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="20" OrdBy="770" ID="633" Name="Measure Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Please note&lt;/strong&gt;: This measure has been updated. The National Quality Measures Clearinghouse is working to update this summary.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="14" OrdBy="780" ID="634" Name="Measure Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The individual measure, &quot;Aspirin Use and Discussion (ASP),&quot; is published in &quot;HEDIS 2014. Healthcare Effectiveness Data and Information Set. Vol. 2, Technical Specifications for Health Plans.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For more information, contact the National Committee for Quality Assurance (NCQA) at 1100 13th Street, NW, Suite 1000, Washington, DC 20005; Phone: 202-955-3500; Fax: 202-955-3599; Web site: &lt;a href=&quot;http://www.ncqa.org/&quot; title=&quot;NCQA Web site&quot;&gt;www.ncqa.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="87" OrdBy="800" ID="636" Name="NQMC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NQMC summary was completed by ECRI Institute on April 30, 2010. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This NQMC summary was updated by ECRI Institute on May 25, 2011, November 26, 2012, May 10, 2013, and again on April 4, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="88" OrdBy="810" ID="637" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For detailed specifications regarding the National Committee on Quality Assurance (NCQA) measures, refer to &lt;em&gt;HEDIS Volume 2: Technical Specifications for Health Plans&lt;/em&gt;, available from the NCQA Web site at &lt;a href=&quot;http://www.ncqa.org/&quot; title=&quot;NCQA Web site&quot;&gt;www.ncqa.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="641" OrdBy="850" Name="Production"><Field FieldID="1" OrdBy="1366" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Committee for Quality Assurance (NCQA). HEDIS 2014: Healthcare Effectiveness Data and Information Set. Vol. 1, narrative. Washington (DC): National Committee for Quality Assurance (NCQA); 2013. various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Committee for Quality Assurance (NCQA). HEDIS 2014: Healthcare Effectiveness Data and Information Set. Vol. 2, technical specifications for health plans. Washington (DC): National Committee for Quality Assurance (NCQA); 2013. various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Committee for Quality Assurance (NCQA). HEDIS 2014: Healthcare Effectiveness Data and Information Set. Vol. 3, specifications for survey measures. Washington (DC): National Committee for Quality Assurance (NCQA); 2013. various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NQMC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.&lt;/p&gt; &lt;p&gt;All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.&lt;/p&gt; &lt;p&gt;Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at &lt;a href=&quot;../about/inclusion-criteria.aspx&quot;&gt;http://www.qualitymeasures.ahrq.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &lt;p&gt;Readers with questions regarding measure content are directed to contact the measure developer.&lt;/p&gt;" /></Field></Section></Version>
